Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin

Diabetes and Vascular Disease Research

Volumn 8, Issue 3, 2011, Pages 195-201

  Naka, Katerina K ^a   Papathanassiou, Katerina ^a   Bechlioulis, Aris ^a   Pappas, Konstantinos ^a   Kazakos, Nikolaos ^a   Kanioglou, Chryssanthi ^a   Papafaklis, Michail I ^a   Kostoula, Aggeliki ^b   Vezyraki, Patra ^a   Makriyiannis, Demetrios ^c   Tsatsoulis, Agathocles ^a   Michalis, Lampros K ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Atherosclerosis; Endothelial function; Insulin; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; ROSIGLITAZONE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIUM FUNCTION; FEMALE; FLOW MEDIATED DILATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; GREECE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 80052076130     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111408628     Document Type: Article

References (32)

1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-950. (Pubitemid 38685285)
2. Davignon J and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-32. (Pubitemid 38786440)
3. Dandona P, Ghanim H, Chaudhuri A and Mohanty P. Thiazolidinediones- improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications 2008; 22: 62-75.
4. Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes-is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 2008; 9: 405-420. (Pubitemid 351291785)
5. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M and Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-490. (Pubitemid 38174076)
6. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27: 1349-1357. (Pubitemid 38679982)
7. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z and Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153: 115-121. (Pubitemid 41038391)
8. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF and Lee YT. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 98: 1057-1062.
9. Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D and Fonseca V. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord 2006; 4: 179-184. (Pubitemid 44613398)
10. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM and Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007; 12: 311-318.
11. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 2007; 195: 138-146. (Pubitemid 47566382)
12. Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008; 31: 121-127.
13. Singh S and Furberg CD. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart 2009; 95: 1-3.
14. Nissen SE and Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
15. Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2010; 95: 203-209.
16. Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, et al. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009; 205: 221-226.
17. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265. (Pubitemid 34084631)
18. Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007; 192: 197-203. (Pubitemid 46602298)
19. Bechlioulis A, Naka KK, Papanikolaou O, Kontostolis E, Kalantaridou SN and Michalis LK. Menopause and hormone therapy: from vascular endothelial function to cardiovascular disease. Hellenic J Cardiol 2009; 50: 303-315.
20. Modena MG, Bonetti L, Coppi F, Bursi F and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-510. (Pubitemid 34833167)
21. Gaenzer H, Neumayr G, Marschang P, Sturm W, Lechleitner M, Foger B, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol 2002; 89: 431-434. (Pubitemid 34142519)
22. Vehkavaara S and Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004; 24: 325-330. (Pubitemid 38197586)
23. Muis MJ, Bots ML, Grobbee DE and Stolk RP. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 2005; 22: 118-126. (Pubitemid 40204316)
24. Hedblad B, Zambanini A, Nilsson P, Janzon L and Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007; 261: 293-305.
25. Stocker DJ, Taylor AJ, Langley RW, Jezior MR and Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153: e441-446.
26. Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, et al. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009; 11: 24-32.
27. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Es GA, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121: 1176-1187.
28. Buch HN, Baskar V, Barton DM, Kamalakannan D, Akarca C and Singh BM. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabet Med 2002; 19: 572-574. (Pubitemid 35300678)
29. Mukhtar R and Reckless JP. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabet Med 2005; 22 Suppl 3: 6-10.
30. Sidhu JS, Cowan D and Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763. (Pubitemid 37433654)
31. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957. (Pubitemid 36506065)
32. Marx N, Duez H, Fruchart JC and Staels B. Peroxisome proliferator- activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178. (Pubitemid 38656403)